Cargando…

Predicting CD137 upregulation on NK cells in patients receiving monoclonal antibody therapy

Detalles Bibliográficos
Autores principales:	Makkouk, Amani, Sundaram, Vandana, Desai, Manisha, Chester, Cariad, Maecker, Holden, Kohrt, Holbrook E
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4645976/ http://dx.doi.org/10.1186/2051-1426-3-S2-P98

Ejemplares similares

Reovirus activated NK cells show enhanced cetuximab mediated antibody-dependent cellular cytotoxicity against colorectal cancer cells
por: Zhao, Xing, et al.
Publicado: (2015)

Boosting antibody-dependant cellular cytotoxicity against tumor cells with a CD137 stimulatory antibody
por: Houot, Roch, et al.
Publicado: (2012)

Natural Killer Cell Immunomodulation: Targeting Activating, Inhibitory, and Co-stimulatory Receptor Signaling for Cancer Immunotherapy
por: Chester, Cariad, et al.
Publicado: (2015)

4-1BB agonism: adding the accelerator to cancer immunotherapy
por: Chester, Cariad, et al.
Publicado: (2016)

Immunotherapeutic approaches to ovarian cancer treatment
por: Chester, Cariad, et al.
Publicado: (2015)

Enhancement of antibody-dependent cell mediated cytotoxicity: a new era in cancer treatment
por: Rajasekaran, Narendiran, et al.
Publicado: (2015)

Immunotherapy of melanoma with the immune costimulatory monoclonal antibodies targeting CD137
por: Li, Shi-Yan, et al.
Publicado: (2013)

CD137-CD137 Ligand Interactions in Inflammation
por: Kwon, Byungsuk
Publicado: (2009)

Costimulatory T cell engagement via a novel bispecific anti-CD137 /anti-HER2 protein
por: Hinner, Marlon J, et al.
Publicado: (2015)

Regulation of CD38 on Multiple Myeloma and NK Cells by Monoclonal Antibodies
por: Wu, Hao-Tian, et al.
Publicado: (2022)

Agonistic Anti-CD137 Monoclonal Antibody Treatment Induces CD11b(+)Gr-1(+) Myeloid-derived Suppressor Cells
por: Lee, Jung-Mi, et al.
Publicado: (2010)

Soluble CD137 as a dynamic biomarker to monitor agonist CD137 immunotherapies
por: Glez-Vaz, Javier, et al.
Publicado: (2022)

An Update on Anti-CD137 Antibodies in Immunotherapies for Cancer
por: Chu, Dinh-Toi, et al.
Publicado: (2019)

Is CD137 Ligand (CD137L) Signaling a Fine Tuner of Immune Responses?
por: Kwon, Byungsuk
Publicado: (2015)

Correction: Soluble CD137 as a dynamic biomarker to monitor agonist CD137 immunotherapies
Publicado: (2023)

Regulatory T Cells Inhibit T Cell Activity by Downregulating CD137 Ligand via CD137 Trogocytosis
por: Luu, Khang, et al.
Publicado: (2021)

The Murine CD137/CD137 Ligand Signalosome: A Signal Platform Generating Signal Complexity
por: Choi, Beom K., et al.
Publicado: (2020)

Increased Soluble CD137 Levels and CD4+ T‐Cell‐Associated Expression of CD137 in Acute Atherothrombotic Stroke
por: He, Yang, et al.
Publicado: (2018)

Human CD81 directly enhances T(h)1 and T(h)2 cell activation, but preferentially induces proliferation of T(h)2 cells upon long-term stimulation
por: Maecker, Holden T
Publicado: (2003)

Normal Lymphocyte Development but Delayed Humoral Immune Response in CD81-null Mice
por: Maecker, Holden T., et al.
Publicado: (1997)

The Roles of CD137 Signaling in Atherosclerosis
por: Jung, In-Hyuk, et al.
Publicado: (2016)

The Progress of Investigating the CD137-CD137L Axis as a Potential Target for Systemic Lupus Erythematosus
por: Mak, Anselm, et al.
Publicado: (2019)

Sequential tumor and dual immune targeted immunotherapy: anti-lymphoma activity of Rituximab with 4-1bb stimulation and PD-1 blockade
por: Mueller, Antonia MS, et al.
Publicado: (2014)

CD137-CD137L Interaction Regulates Atherosclerosis via Cyclophilin A in Apolipoprotein E-Deficient Mice
por: Li, Yuefeng, et al.
Publicado: (2014)

Hypoxia-induced soluble CD137 in malignant cells blocks CD137L-costimulation as an immune escape mechanism
por: Labiano, Sara, et al.
Publicado: (2014)

CD137 Agonists Targeting CD137-Mediated Negative Regulation Show Enhanced Antitumor Efficacy in Lung Cancer
por: Yi, Ling, et al.
Publicado: (2022)

CD137 Expression Is Induced by Epstein-Barr Virus Infection through LMP1 in T or NK Cells and Mediates Survival Promoting Signals
por: Yoshimori, Mayumi, et al.
Publicado: (2014)

CD137(+) T-Cells: Protagonists of the Immunotherapy Revolution
por: Ugolini, Alessio, et al.
Publicado: (2021)

CD137 Signaling Promotes Endothelial Apoptosis by Inhibiting Nrf2 Pathway, and Upregulating NF-κB Pathway
por: Geng, Tianxin, et al.
Publicado: (2020)

CD16(+)NK-92 and anti-CD123 monoclonal antibody prolongs survival in primary human acute myeloid leukemia xenografted mice
por: Williams, Brent A., et al.
Publicado: (2018)

The co-inhibitory receptor TIGIT regulates NK cell function and is upregulated in human intrahepatic CD56(bright) NK cells
por: Ziegler, Annerose E., et al.
Publicado: (2023)

Identification of CD137-Expressing B Cells in Multiple Sclerosis Which Secrete IL-6 Upon Engagement by CD137 Ligand
por: Wong, Hiu Yi, et al.
Publicado: (2020)

CD137 ligand feedback upregulates PD‐L1 expression on lung cancer via T cell production of IFN‐γ
por: Wang, Helin, et al.
Publicado: (2019)

4-1BB (CD137) in anticancer chimeras
por: Melero, Ignacio, et al.
Publicado: (2020)

CD137 expression in cancer cells: regulation and significance
por: Glorieux, Christophe, et al.
Publicado: (2019)

CD137, an attractive candidate for the immunotherapy of lung cancer
por: Ye, Lingyun, et al.
Publicado: (2020)

Contributions of Costimulatory Molecule CD137 in Endothelial Cells
por: Yuan, Wei, et al.
Publicado: (2021)

Development of a Bispecific Antibody Targeting CD30 and CD137 on Hodgkin and Reed-Sternberg Cells
por: Rajendran, Sakthi, et al.
Publicado: (2019)

The optimal interval before receiving SARS-COV-2 vaccination for patients who have received Anti-CD 20 monoclonal antibodies
por: Liu, Kexin, et al.
Publicado: (2022)

Re-Evaluating the Effects of Obesity on Cancer Immunotherapy Outcomes in Renal Cancer: What Do We Really Know?
por: Farag, Kristine I., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_fckmqufo3nt5u9uv2og900470s